Search

Your search keyword '"Orfanidou, Afroditi"' showing total 5 results
Start Over Author "Orfanidou, Afroditi" Publication Year Range Last 3 years
5 results on '"Orfanidou, Afroditi"'

2. Hepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: A multicentre cohort study

Author

Papatheodoridi, Margarita Su, Tung-Hung Hadziyannis, Emilia and Liao, Chun-Hsun Orfanidou, Afroditi Yang, Hung-Chi Zachou, Kalliopi Liu, Chun-Jen Kourikou, Anastasia Gatselis, Nikolaos Manolakopoulos, Spilios Dalekos, George Kao, Jia-Horng Hadziyannis, Stephanos Papatheodoridis, V, George

Subjects
digestive system diseases
Abstract

Background and Aims Scarce data exist on the effect of nucleos(t)ide analogue (NA) discontinuation on hepatocellular carcinoma (HCC) risk in HBeAg-negative chronic hepatitis B (CHBe-). Therefore, we assessed whether HCC risk is increased in non-cirrhotic CHBe- patients who discontinue compared to those remaining on NAs. Methods This cohort study included 650 consecutive non-cirrhotic Caucasian or Asian patients with CHBe- without a history of HCC who discontinued NAs after a median of 5 or 3 years (cases, n = 325; Caucasians: 143, Asians: 182) or remained on NA therapy beyond 5 or 3 years respectively (controls, n = 325; Caucasians: 223, Asians: 102). Propensity score (PS) 1:1 matching was applied to adjust for patients’ origin, age and sex. Results During a median follow-up of 44 months, HCC developed in 7/325 cases and 9/325 controls or 7/245 PS-matched cases and 7/245 PS-matched controls with 5-year cumulative HCC incidence of 5.1% and 4.9% respectively (log-rank, P = .836). No difference in 5-year HCC risk was observed between cases and controls of Caucasian (3.0% vs 4.8%; log-rank, P = .510) or Asian origin (1.3% vs 2.2%; log-rank, P = .873). In both cases and controls, HCC incidence was independently associated with age and PAGE-B score. In cases alone, HCC development after NA discontinuation was associated only with pretreatment platelet counts and PAGE-B score, but not with any type of relapse or HBsAg loss. Conclusions Our findings suggest that discontinuation of effective long-term NA therapy in non-cirrhotic CHBe- patients are not associated with increased HCC risk, which is not affected by post-NA relapses and/or HBsAg loss.

Published
2022

3. The efficacy of immunomodulators in the prevention and suppression of anti-drug antibodies to anti-tumor necrosis factor therapy in inflammatory bowel disease

Author

Fousekis, Fotios S. Papamichael, Konstantinos Kourtis, Georgios and Albani, Eleni N. Orfanidou, Afroditi Saridi, Maria and Katsanos, Konstantinos H. Christodoulou, Dimitrios K.

Subjects
digestive system diseases
Abstract

The development of biological agents against tumor necrosis factor (TNF) has revolutionized the management of inflammatorybowel disease (IBD), frequentlyachieving induction and maintenance of remission in both ulcerative colitis and Crohn’s disease. However, a loss of response due to the development of anti-drug antibodies (ADA) is seen annually in approximately 20% of IBD patients receiving anti-TNF therapy. Current evidence suggests that the use of immunomodulators (IMM), such as thiopurines (azathioprine and 6-mercaptopurine) or methotrexate, may prevent or suppress ADA formation. In this article, we present a comprehensive review of the available literature regarding the efficacy of IMM in the prevention and suppression of ADA development to anti-TNF therapy in patients with IBD.

Published
2022

4. Efficacy of citalopram or amitriptyline versus no treatment in patients with functional chest pain.

Author

Voulgaris, Theodoros, Lekakis, Vassileios, Vlachogiannakos, Jiannis, Kamberoglou, Dimitrios, Orfanidou, Afroditi, Papatheodoridis, George, and Karamanolis, George

Subjects
CHEST pain, AMITRIPTYLINE, ESOPHAGEAL motility disorders, CITALOPRAM, VISCERAL pain, EOSINOPHILIC esophagitis
Abstract

Background Functional chest pain (FCP) is characterized by the presence of chest pain of presumed esophageal origin, but with a negative workup on routine investigations, including ruling out gastroesophageal reflux disease (GERD). Antidepressants are frequently prescribed to treat FCP and are presumed to act as neuromodulators of visceral hypersensitivity. However, there is little evidence of their efficacy in patients with FCP. We retrospectively assessed the efficacy of citalopram or amitriptyline vs. no treatment in patients with FCP. Methods Esophageal diseases, including GERD, eosinophilic esophagitis and major esophageal motility disorders, were excluded. Thus, patients with established FCP according to Rome IV criteria were included in the study. Then, patients treated for at least 3 months with citalopram 20 mg, amitriptyline 50 mg, or observation were selected. The primary endpoint was complete disappearance or significant amelioration of symptoms at the end of treatment. Results Over a 5-year period, 102 patients (74 female; mean age 49±10 years) were diagnosed with FCP and were recognized to have received once daily citalopram (n=32), amitriptyline (n=34), or no treatment (n=36). After a 3-month follow up, improvement in chest pain was reported by 16 (47.1%) patients treated with citalopram, 18 (56.3%) patients treated with amitriptyline, and 4 (11.1%) patients without treatment (P=0.02 and 0.01 for no treatment vs. citalopram and amitriptyline therapy, respectively). Conclusion Both citalopram and amitriptyline are effective pharmacological options in the symptomatic relief of almost 50% patients with well characterized FCP. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

5. The efficacy of immunomodulators in the prevention and suppression of anti-drug antibodies to anti-tumor necrosis factor therapy in inflammatory bowel disease.

Author

Fousekis, Fotios S., Papamichael, Konstantinos, Kourtis, Georgios, Albani, Eleni N., Orfanidou, Afroditi, Saridi, Maria, Katsanos, Konstantinos H., and Christodoulou, Dimitrios K.

Subjects
INFLAMMATORY bowel diseases, CROHN'S disease, IMMUNOMODULATORS, ULCERATIVE colitis, TUMOR necrosis factors
Abstract

The development of biological agents against tumor necrosis factor (TNF) has revolutionized the management of inflammatory bowel disease(IBD), frequently achieving induction and maintenance of remission in both ulcerative colitis and Crohn’s disease. However, a loss of response due to the development of anti-drug antibodies (ADA) is seen annually in approximately 20% of IBD patients receiving anti-TNF therapy. Current evidence suggests that the use of immunomodulators (IMM), such as thiopurines (azathioprine and 6-mercaptopurine) or methotrexate, may prevent or suppress ADA formation. In this article, we present a comprehensive review of the available literature regarding the efficacy of IMM in the prevention and suppression of ADA development to anti-TNF therapy in patients with IBD. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results